Ambys Medicines Revenue and Competitors
Estimated Revenue & Valuation
- Ambys Medicines's estimated annual revenue is currently $1.7M per year.
- Ambys Medicines's estimated revenue per employee is $77,500
- Ambys Medicines's total funding is $187M.
Employee Data
- Ambys Medicines has 22 Employees.
- Ambys Medicines grew their employee count by -80% last year.
Ambys Medicines's People
| Name | Title | Email/Phone |
|---|
Ambys Medicines Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Ambys Medicines?
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.
keywords:N/A
$187M
Total Funding
22
Number of Employees
$1.7M
Revenue (est)
-80%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ambys Medicines News
Ambys Medicines Expands Leadership Team with Key Appointments in Human Resources and Finance Functions. April 20, 2022 08:00 AM Eastern Daylight...
Ambys Medicines Inc., of South San Francisco, appointed Samira Shaikhly chief human resources officer and John McKeon vice president of...
... Vifor Pharma (I), Ambys Medicines (I), Global Blood Therapeutics (I) ... American Regent (I), Disc Medicine (I), Blue Note Therapeutics,...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company founded to capitalize on advances in liver biology and regenerative medicines to develop therapies for serious liver diseases, launched today with a $60 million Series A financing funded by Third Rock Ventures and Takeda. As part ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 23 | 0% | N/A |
#2 | $3.6M | 23 | 5% | N/A |
#3 | $3.7M | 24 | 0% | N/A |
#4 | $3.7M | 24 | -14% | N/A |
#5 | $2.4M | 24 | N/A | N/A |